Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis

@article{Slee2019PharmacologicalTF,
  title={Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis},
  author={April Slee and Irwin Nazareth and Paulina Bondaronek and Yifeng Liu and Zhihang Cheng and Nick Freemantle},
  journal={The Lancet},
  year={2019},
  volume={393},
  pages={768-777}
}
BACKGROUND Generalised anxiety disorder is a disease that can be associated with substantial dysfunction. Pharmacological treatment is often the first choice for clinicians because of the cost and resource constraints of psychological alternatives, but there is a paucity of comparative information for the multiple available drug choices. METHODS A systematic review and network meta-analysis was performed on randomised trials in adult outpatients with generalised anxiety disorder identified… Expand
Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis of Double-Blind Randomized Controlled Trials
  • Wenqiang Kong, Huiyuan Deng, +4 authors Xiuling Wang
  • Medicine
  • Frontiers in Pharmacology
  • 2020
TLDR
Only agomelatine manifested better remission with relatively good tolerability, however, the others were worse than placebo in terms of tolerability but these results were limited by small sample sizes. Expand
Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis.
TLDR
Most drugs are more effective than placebo, and there are few significant differences between the active drugs and placebo on acceptability. Expand
Pharmacological treatments for generalised anxiety disorder – Authors' reply
TLDR
The bias assessment approach advocated by Munkholm and colleagues could be considered overly nihilistic, especially for trials in mental health, and the goal was to produce a transparent and robust review of the relevant evidence to inform health policy, rather than to develop clinical guidelines. Expand
Pharmacological treatments for adults with post-traumatic stress disorder: A network meta-analysis of comparative efficacy and acceptability.
TLDR
The NMA supports topiramate, risperidone, quetiapine, parxetine, venlafaxine, fluoxetine and sertraline as effective pharmacological choices for the treatment of PTSD. Expand
Probiotics for the treatment of depression and anxiety: A systematic review and meta-analysis of randomized controlled trials.
TLDR
The current review suggests that probiotics may improve symptoms of depression and anxiety in clinical patients, however, given the limitations in the included studies, RCTs with long-term follow-up and large sample sizes are needed. Expand
Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT
TLDR
The main objective of the PANDA research programme was to provide more guidance about when antidepressants are likely to benefit people with depression, and it was found that the minimal clinically important difference varies considerably with the initial severity of depressive and anxiety symptoms. Expand
The largest meta-analysis of pharmaceutical treatments of Generalised Anxiety Disorder consolidates current knowledge and reveals convincing effectiveness of Venlafaxine
  • S. Roles
  • Medicine
  • Evidence Based Journals
  • 2019
TLDR
This paper identified the volumes of evidence surrounding psychopharmacology for Generalised Anxiety Disorder (GAD) which existed in isolated databases making it difficult to navigate, and drew helpful and practical conclusions. Expand
Trends in generalised anxiety disorders and symptoms in primary care: UK population-based cohort study
TLDR
A substantial increase in general practitioner consulting for generalised anxiety and depression recently is observed, concentrated within younger people and in particular women. Expand
Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine
TLDR
Agomelatine, a melatonin receptor agonist and serotonin 2C (5-HT2C) receptor antagonist, has been shown to have efficacy that is greater than placebo in patients with GAD, and to have a tolerability profile that compares favourably with that of escitalopram. Expand
Pharmacological treatments for generalised anxiety disorder
TLDR
There are serious doubts on the validity and reliability of the data from at least 15 trials published in China and reviewers should do their best to verify the studies they included, and if necessary, to contact the authors to assess the quality of studies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
TLDR
Though the frequentist analysis was inconclusive because of a high level of uncertainty in effect sizes, the probabilistic analysis, which did not rely on significant outcomes, showed that fluoxetine and sertraline seem to have some advantages over other treatments. Expand
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis
TLDR
This work aimed to update and expand previous work to compare and rank antidepressants for the acute treatment of adults with unipolar major depressive disorder, and found that all antidepressants were more effective than placebo. Expand
Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials
TLDR
Despite its low acceptability and tolerability, the use of 50–150 mg/day quetiapine-XR for adult GAD patients may be considered as an alternative treatment. Expand
Evidence-Based Review of Clinical Outcomes of Guideline-Recommended Pharmacotherapies for Generalized Anxiety Disorder
TLDR
There is inadequate evidence to formulate recommendations based on the pooled results from this study alone, however, such analysis provides an additional resource for clinicians to make more effective treatment decisions for individual patients with GAD. Expand
Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis
TLDR
PGB was superior to placebo for the amelioration of GAD symptoms and was comparable to benzodiazepines in clinical response, but had lower dropout rates than Benzodiazepine. Expand
Evidence-based pharmacological treatment of generalized anxiety disorder.
TLDR
It is difficult to predict reliably which patients will respond well to pharmacological treatment, but response to antidepressants is unlikely if there is no evidence of an onset of effect within 4 wk, and continuing treatment for at least 12 months is recommended. Expand
Efficacy of treatments for anxiety disorders: a meta-analysis
TLDR
In direct comparisons with control groups, all investigated drugs, except for citalopram, opipramol and moclobemide, were significantly more effective than placebo; this finding cannot be explained by heterogeneity, publication bias or allegiance effects. Expand
A clinical research practice datalink analysis of antidepressant treatment patterns and health care costs in generalized anxiety disorder.
TLDR
The significant rate of AD discontinuation and associated treatment duration indicate unmet needs among patients with GAD, and substantial health care costs were also observed in this study. Expand
Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.
TLDR
Routine use of selective serotonin reuptake inhibitors as the first line treatment of depressive illness may greatly increase cost with only questionable benefit, according to meta-analysis of 63 randomised controlled trials. Expand
The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
  • R. McIntyre
  • Medicine
  • Neuropsychiatric disease and treatment
  • 2017
TLDR
Evidence suggests that vilazodone may be particularly well suited for depressed patients with high anxiety levels, and vortioxetine and levomilnacipran ER are considered as second-line treatments due to lack of relapse prevention data at the time of approval. Expand
...
1
2
3
...